Johnson & Johnson's (JNJ) Q4 earnings and revenue estimates were nudged higher before results on Wednesday, BofA Securities said Friday in a report.
The firm's estimate for per-share earnings rose to $2.08 from $2.03 with revenue forecast at $22.61 billion, up from $22.52 billion, the report said.
In 2025 and 2026, BofA said estimates are "slightly lower" with sales in the medical technology segment seen easing, and underlying EPS estimates are down on "lower revenues, higher currency headwinds, and tax."
BofA said the focus of the Q4 earnings call will likely include an indication of the impact of the acquisition of Intra-Cellular Therapies (ITCI), along with currency fluctuations seen as a "material headwind to reported sales and EPS."
BofA cut the price target on Johnson & Johnson to $160 from $166 and reiterated its neutral rating.
Price: 147.24, Change: -0.53, Percent Change: -0.36
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。